Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening
Príomhchruthaitheoirí: | Martin, RM, Dixon, PC, Turner, E, Keeney, E |
---|---|
Formáid: | Journal article |
Teanga: | English |
Foilsithe / Cruthaithe: |
Wiley
2022
|
Míreanna comhchosúla
-
Prostate cancer: estimating the benefits of PSA screening.
de réir: Vickers, A, et al.
Foilsithe / Cruthaithe: (2009) -
Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: The CAP randomized clinical trial
de réir: Martin, RM, et al.
Foilsithe / Cruthaithe: (2018) -
On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
de réir: Bangma, C, et al.
Foilsithe / Cruthaithe: (2010) -
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP).
de réir: Thorn, J, et al.
Foilsithe / Cruthaithe: (2016) -
Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo.
de réir: Denmeade, SR, et al.
Foilsithe / Cruthaithe: (2003)